GlassScriptPhysician profile
Roberto A Bacani
NPI 1669448684
$2,449.53
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $253 · 2021: $475 · 2022: $450 · 2023: $294 · 2024: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $608 · Education: $11.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.10 |
| Education | $11.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $335.22 | 2019-2023 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $266.20 | 2021-2024 | |
| Vifor Pharma, INC. | $255.98 | 2019-2023 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $214.77 | 2019-2023 | Auryxia |
| Astrazeneca Pharmaceuticals LP | $159.14 | 2019-2023 | Farxiga |
| Mallinckrodt Hospital Products INC. | $155.09 | 2021-2024 | Acthar |
| Bard Peripheral Vascular, INC. | $148.70 | 2019 | |
| Alexion Pharmaceuticals, INC. | $136.02 | 2019-2023 | |
| Glaxosmithkline, LLC. | $126.67 | 2021-2024 | Jesduvroq, Benlysta |
| Travere Therapeutics, INC. | $105.97 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $84.43 | 2021-2024 | |
| Amgen INC. | $74.29 | 2020-2024 | Tavneos |
| Aurinia Pharma U.S., INC. | $71.22 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $57.59 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $56.24 | 2022-2024 | Rayaldee |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $56.10 | 2019 | |
| Mallinckrodt Enterprises LLC | $50.45 | 2019 | |
| Ardelyx, INC. | $28.78 | 2024 | Ibsrela |
| Genzyme Corporation | $18.98 | 2019 | |
| Lilly USA, LLC | $18.57 | 2024 | Jardiance |
| Horizon Therapeutics Plc | $17.83 | 2022 | |
| Daiichi Sankyo INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Bacani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.